On behalf of the CLiC Leaders, we invite you to participate in the following poll. Click here to answer.
Note that the following questions refer to the MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Carolyn Owen’s podcast available here.
1. Based on the MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Owen’s podcast, should MRD testing (positive MRD) be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed?
- Yes
- No
- Maybe
2. Based on the MURANO 48-month data, should high risk cytogenetics be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed?
- Yes
- No
- Maybe
3. Based on the MURANO 48-month data, should everyone stop treatment at 24 months?
- Yes
- No
- Maybe
